• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Faraday Future Late Wednesday Announces Yun Han Named Chief Accounting Officer And Interim CFO, And Funding Progress, Initial Funding Expected This Week Under $60M Financing Agreement

    10/27/22 6:16:37 AM ET
    $FFIE
    $IBRX
    $RMO
    Auto Manufacturing
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FFIE alert in real time by email

    - Yun Han named Chief Accounting Officer and Interim Chief Financial Officer -

    - Initial Funding Expected This Week Under $60 Million Financing Agreement -

    Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") (NASDAQ:FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Ms. Han replaces Becky Roof, who served as interim Chief Financial Officer until October 12, 2022, and is assisting the Company to ensure an orderly transition.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221026006161/en/

    Faraday Future today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. (Photo: Business Wire)

    Prior to joining Faraday Future, Ms. Han was Senior Vice President and Chief Accounting Officer at Romeo Power, Inc (NYSE:RMO). She was previously Vice President and Controller at Immunity Bio, Inc. (NASDAQ:IBRX), and held other senior accounting and finance positions at various companies. Earlier, she spent over 13 years with Price Waterhouse Coopers LLC's technical accounting and audit practice. She is a Certified Public Accountant licensed in the State of California and a graduate of the University of Southern California.

    "I am pleased to welcome Ms. Han as our Chief Accounting Officer and interim Chief Financial Officer. Yun's background, training, and industry experience make her ideally suited to join the leadership team at Faraday Future. I look forward to working closely with her to further strengthen our finance and accounting team, and to raise the additional funds required to deliver on our promise to bring the FF 91 to market as quickly as possible," said Dr. Carsten Breitfeld, Global CEO of Faraday Future.

    The Company also announced that it has received all of the previously announced $55 million financing (other than $5 million of additional bridge notes) from an affiliate of ATW Partners LLC as expected and anticipates receiving the first $10 million under the previously announced $60 million financing agreement this week. Certain additional proceeds are subject to the achievement of additional milestones and other factors as detailed in the Company's Form 8-K dated October 25, 2022. The Company filed a Form 8-K on October 26, 2022 which provides further information on the Company's current financial position.

    The Company continues to work diligently to raise the additional funds needed to fund its operations through the start of production, first deliveries, and beyond. "Faraday Future appreciates the effort of our largest shareholder FF Top Holdings LLC along with the exceptional work of my fellow board member Bob Ye, both of whom were instrumental in securing these new funds which bring us closer to delivering the FF 91," said Dr. Breitfeld. "Our factory is nearing completion, our car is meeting or exceeding performance specifications, and when we bring the FF 91 Futurist to market, we will reset consumer expectations for what an intelligent TechLuxury car should be," continued Dr. Breitfeld.

    Users can preorder an FF 91 Futurist via the FF Intelligent App or through our website (English): https://www.ff.com/us/preorder/ or (Chinese): https://www.ff.com/cn/preorder/

    Download the new FF Intelligent App (English): https://apps.apple.com/us/app/id1454187098 or https://play.google.com/store/apps/details?id=com.faradayfuture.online, (Chinese): http://appdownload.ff.com

    Get the next $FFIE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FFIE
    $IBRX
    $RMO

    CompanyDatePrice TargetRatingAnalyst
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    ImmunityBio Inc.
    $IBRX
    5/20/2025$5.00Neutral → Overweight
    Piper Sandler
    ImmunityBio Inc.
    $IBRX
    3/6/2025$8.00Buy
    H.C. Wainwright
    ImmunityBio Inc.
    $IBRX
    1/10/2025$6.00Buy
    BTIG Research
    ImmunityBio Inc.
    $IBRX
    5/12/2023$10.00 → $4.00Overweight → Neutral
    Piper Sandler
    Faraday Future Intelligent Electric Inc.
    $FFIE
    8/16/2022Buy → Hold
    The Benchmark Company
    ImmunityBio Inc.
    $IBRX
    8/3/2022$8.00Buy
    Jefferies
    Romeo Power Inc.
    $RMO
    3/2/2022Buy → Neutral
    BTIG
    More analyst ratings

    $FFIE
    $IBRX
    $RMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Simon Barry J. sold $900,788 worth of shares (75,000 units at $12.01), decreasing direct ownership by 3% to 2,850,821 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/26/26 8:12:26 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Selecky Christobel exercised 25,000 shares at a strike of $2.98 and sold $250,000 worth of shares (25,000 units at $10.00) (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:58 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Soon-Shiong Patrick converted options into 114,329 shares and covered exercise/tax liability with 58,170 shares, increasing direct ownership by 0.19% to 29,757,911 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:07 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FFIE
    $IBRX
    $RMO
    SEC Filings

    View All

    SEC Form 10-K filed by ImmunityBio Inc.

    10-K - ImmunityBio, Inc. (0001326110) (Filer)

    2/23/26 5:24:30 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmunityBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ImmunityBio, Inc. (0001326110) (Filer)

    2/23/26 7:06:39 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmunityBio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ImmunityBio, Inc. (0001326110) (Filer)

    2/18/26 9:02:52 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FFIE
    $IBRX
    $RMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global Chief Executive Officer Aydt Matthias bought $100 worth of Series A Preferred Stock (1 units at $100.00) (SEC Form 4)

    4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

    1/30/25 9:36:52 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    Global Chief Exec. Officer Aydt Matthias disposed of $100 worth of Series A Preferred Stock (1 units at $100.00) and bought $100 worth of Series A Preferred Stock (1 units at $100.00), decreasing direct ownership by 50% to 1 units (SEC Form 4)

    4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

    6/25/24 4:11:43 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    Aydt Matthias bought $100 worth of Series A Preferred Stock (1 units at $100.00) (SEC Form 4)

    4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

    12/27/23 5:23:13 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    $FFIE
    $IBRX
    $RMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $FFIE
    $IBRX
    $RMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

    The QUILT-2.005 randomized clinical trial is on track for final analysis and supplemental Biologics License Application (BLA) submission in 2026 for the BCG-naïve NMIBC carcinoma in situ with or without papillary indication with no additional enrollment required The Independent Data Monitoring Committee (IDMC) confirmed that the fully enrolled study (N=366) is adequately powered to detect the pre-specified difference in complete response rate between the experimental and control arms, and that no additional enrollment is required A planned interim analysis was conducted by the IDMC per the protocol once 50% of enrolled patients (N=183) in Cohort A were evaluable for the primary e

    3/26/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

    Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based review referencing prior FDA and EMA decisions First ANKTIVA authorization in Asia, supporting ongoing global expansion across 34 countries and territories ImmunityBio, Inc. ((IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People's Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln). The approval establishes ANKTIVA's initial presence in Asia and reflects the

    3/20/26 1:08:00 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

    Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1. ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease. This update expands previous NCCN clinical guideline r

    3/17/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research resumed coverage on ImmunityBio with a new price target

    BTIG Research resumed coverage of ImmunityBio with a rating of Buy and set a new price target of $13.00

    3/12/26 8:52:16 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmunityBio upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded ImmunityBio from Neutral to Overweight and set a new price target of $5.00

    5/20/25 8:01:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on ImmunityBio with a new price target

    H.C. Wainwright initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $8.00

    3/6/25 7:26:14 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FFIE
    $IBRX
    $RMO
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Faraday Future Appoints Tommy Zhao as Senior Director of FF Par Sales and After-Sales to Help Drive Future FF and FX Sales

    Mr. Zhao will be responsible for leading FF's Par Sales and After-Sales department and functions. Mr. Zhao's career experience includes both consulting roles as well as numerous automotive-focused executive leadership roles, including VP of Sales, Commercial Strategy & Special Vehicle Operations, focused on Jaguar Land Rover in China and a host of premium retail experiences in the luxury segment including Porsche. Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) ("FF," "Faraday Future," or the "Company"), a California-based global intelligent electric mobility company, today announced the appointment of Tommy Zhao as Senior Director of FF Par Sales and After-Sales. This press

    2/4/25 8:57:00 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    Faraday Future to Empower Strategic Growth through Key Proposals at Next Extraordinary General Meeting

    Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) ("Faraday Future" or the "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced plans to host an Extraordinary General Meeting of Stockholders (the "EGM") on March 7, 2025, to seek approval for proposals aimed at supporting the Company's strategic initiatives and long-term growth. The Company urges all stockholders to vote FOR all proposals. Proposal Highlights Share Authorization Proposal Approval of an amendment to the Company's Charter to increase the number of authorized shares of Common Stock by 25,000,000, from 104,245,313 to 129,245,313, representing a 24% increase. Thi

    1/31/25 7:00:00 AM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    $FFIE
    $IBRX
    $RMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Faraday Future Intelligent Electric Inc.

    SC 13G/A - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

    11/14/24 4:56:24 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    SEC Form SC 13G filed by Faraday Future Intelligent Electric Inc.

    SC 13G - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

    10/8/24 8:03:22 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    SEC Form SC 13G filed by Faraday Future Intelligent Electric Inc.

    SC 13G - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

    9/16/24 7:35:11 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    $FFIE
    $IBRX
    $RMO
    Financials

    Live finance-specific insights

    View All

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

    Q3 2025 Revenue and Other Income Growth with Continued Strong Sales Momentum: $33.7 million of total revenue and other income, up from $26.4 million in Q2 2025. Product Revenue: Up 434% in Q3 2025 versus Q3 2024, with year-to-date sales of $74.7 million. ANKTIVA® Unit Growth: 467% unit sales volume growth in year-to-date 2025 compared to fiscal year 2024. Cash Position: $257.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, up from $153.7 million as of June 30, 2025. Glioblastoma: Early results from the first five recurrent glioblastoma patients treated with ANKTIVA plus the Optune Gio® device in combination with PD-L1 CAR-NK showed 100% disea

    11/4/25 10:12:00 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

    Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of approximately $43 million. ANKTIVA® Unit Growth Since J-code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024. Cash Position: $153.7 million in cash, cash equivalents and marketable securities as of June 30, 2025, with additional $80 million equity financing closed in July 2025, with warrants which could result in an additional gross proceeds of up to approximately $96.0 million. Non-Small Cell Lung Cancer (NSCLC): ImmunityBio has launched ResQ201A, a randomized controlled trial (RCT), in the U.S., evaluating its IL-15 superagonist N-803 in combi

    8/5/25 7:00:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care